Literature DB >> 30831175

Drug-Eluting Stent Implantation and Long-Term Survival Following Peripheral Artery Revascularization.

Eric A Secemsky, Harun Kundi, Ido Weinberg, Marc Schermerhorn, Joshua A Beckman, Sahil A Parikh, Michael R Jaff, Jihad Mustapha, Kenneth Rosenfield, Robert W Yeh.   

Abstract

Year:  2019        PMID： 30831175     DOI： 10.1016/j.jacc.2019.02.020

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  13 in total

1.  State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet?

Authors:  Ramya C Mosarla; Ehrin Armstrong; Yonatan Bitton-Faiwiszewski; Peter A Schneider; Eric A Secemsky
Journal:  J Soc Cardiovasc Angiogr Interv       Date:  2022-08-20

2.  Paclitaxel-Coated Balloons and Stents for Lower Extremity Peripheral Arterial Disease Interventions: A Regulatory Perspective for the Practicing Clinician.

Authors:  Saraschandra Vallabhajosyula; Alexandra J Greenberg-Worisek; Rajiv Gulati; Saarwaani Vallabhajosyula; Anthony J Windebank; Sanjay Misra; Gregory W Barsness
Journal:  Mayo Clin Proc       Date:  2020-08       Impact factor: 7.616

Review 3.  Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel.

Authors:  Peter A Schneider; Ramon L Varcoe; Eric Secemsky; Marc Schermerhorn; Andrew Holden
Journal:  J Vasc Surg       Date:  2020-09-02       Impact factor: 4.268

4.  Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis.

Authors:  Krishna J Rocha-Singh; Sue Duval; Michael R Jaff; Peter A Schneider; Gary M Ansel; Sean P Lyden; Christopher M Mullin; John P A Ioannidis; Sanjay Misra; Abraham R Tzafriri; Elazer R Edelman; Juan F Granada; Christopher J White; Joshua A Beckman
Journal:  Circulation       Date:  2020-05-06       Impact factor: 29.690

Review 5.  Femoral-popliteal peripheral artery disease: From symptom presentation to management and treatment controversies.

Authors:  Anna K Krawisz; Aishwarya Raja; Eric A Secemsky
Journal:  Prog Cardiovasc Dis       Date:  2021-02-13       Impact factor: 8.194

6.  Rationale and Design of the SAFE-PAD Study.

Authors:  Eric A Secemsky; Aishwarya Raja; Changyu Shen; Linda R Valsdottir; Marc Schermerhorn; Robert W Yeh
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2021-01-13

7.  Is There a Real Association Between Paclitaxel Devices and Mortality? Time to Pause and Re-Evaluate What We Know About This Statistical Finding.

Authors:  Mehdi H Shishehbor; Eric A Secemsky; Ramon L Varcoe
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

8.  Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.

Authors:  William A Gray; Michael R Jaff; Sahil A Parikh; Gary M Ansel; Marianne Brodmann; Prakash Krishnan; Mahmood K Razavi; Frank Vermassen; Thomas Zeller; Roseann White; Kenneth Ouriel; Mark A Adelman; Sean P Lyden
Journal:  Circulation       Date:  2019-09-30       Impact factor: 29.690

9.  Retrospective Real-World Studies of Paclitaxel and Mortality: Defining the Many Faces of Bias.

Authors:  Krishna J Rocha-Singh
Journal:  JACC Cardiovasc Interv       Date:  2020-05-14       Impact factor: 11.195

Review 10.  Current developments in endovascular therapy of peripheral vascular disease.

Authors:  Damianos G Kokkinidis; Ehrin J Armstrong
Journal:  J Thorac Dis       Date:  2020-04       Impact factor: 3.005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.